Product Overview
Sermorelin 5mg from Dragon Pharma is a single lyophilised vial of a peptide that belongs to the growth hormone releasing hormone family. It is the shortened 1-29 fragment of GHRH, so its action is to tell the pituitary to release growth hormone on its own rather than to deliver growth hormone from outside. That distinction is the whole point of the molecule and the reason it is discussed next to secretagogues instead of next to Dragontropin HGH, which supplies the finished hormone.
The signal is short. The parent GHRH(1-29)-amide has a measured half-life of 6.2 minutes in a rat intravenous model, vendor texts quote 10-20 minutes, and no human value is established in the sources checked for this card. Whatever the exact figure, the practical consequence is the same: a pulse that fades quickly, which is why the material is injected daily and timed close to natural nocturnal release. A single weekly injection would not reproduce that pattern.
The code sold here is research-grade powder. The pharmacy version of sermorelin, Geref, is no longer manufactured, so there is no current prescription product to point to for a dose, and no human sports dose has been confirmed in peer-reviewed work. Related material on the same shelf includes Ipamorelin 5mg and Hexarelin 5mg from the ghrelin side and CJC-1295 Dac 5mg from the same GHRH side, which makes the family easy to compare but also easy to confuse.
Dosage Protocol
There is no approved dosing for a research vial and no confirmed human sports dose, so the table reports the vendor research pattern and labels it as such rather than presenting it as settled practice.
| Baseline research amount | The vendor grading starts at a low daily amount and describes an advanced level at 400-500 mcg a day; a human dose for performance purposes is not confirmed by peer-reviewed sources |
| Intermediate | Same range, held for weeks rather than days, with the response judged on sleep and recovery |
| Advanced | 400-500 mcg a day in the vendor material; nothing in the literature confirms a higher amount as more effective |
| Female | No confirmed female protocol was found for the research vial, so none is quoted here |
| Administration | Subcutaneous injection, daily, usually before sleep; the pulse is short, so frequency matters more than a single large amount |
Mixing is straightforward with a 5 mg vial. Adding 1 ml of bacteriostatic water gives 5 mg per ml, adding 2 ml gives 2.5 mg per ml, and the drawn volume changes accordingly. The reconstituted solution belongs in the refrigerator, and the powder itself should stay cold, dry and away from light.
Stacking Within the Peptide Line
The family is deliberately paired because its members knock on different doors. Sermorelin is a GHRH analog; Ipamorelin 5mg is a ghrelin receptor agonist, so one is not a duplicate of the other. The cards below show the combinations discussed in the material, and each tile opens the product page.
What to Expect
- Sleep and recovery come first. Users report changes in that department within the first weeks, long before anything shows in body composition.
- A pulse, not a level. Growth hormone rises briefly after each injection, which is the reason for daily administration rather than a weekly schedule.
- Body composition moves in months. The effects accumulate over the 12-16 week vendor cycle, not in a fortnight.
- The half-life figure is not settled. 6.2 minutes was measured in rats using the parent compound, 10-20 minutes is the vendor claim, and no human value exists.
- No confirmed human dose. The 400-500 mcg a day level is a vendor figure; peer-reviewed sources do not confirm a performance dose.
- Class effects apply. Oedema, fluid retention and injection site reactions are described for the GH-peptide group as a whole.
- Testing. The substance appears by name in WADA class S2, where the ban applies at all times, which matters for anyone subject to testing.
Side Effects and Management
Daily injections and fluid shifts make up most of the profile. Almost everything listed here responds to a lower amount or a pause rather than to another product.
Between Blocks and Follow-Up
This peptide does not suppress testosterone production, so the recovery question is about the protocol cycle rather than about the gonadal axis. The vendor pattern leaves a gap between blocks, and the follow-up looks at markers that a growth hormone pulse can move.
